Claims for Patent: 8,772,458

Summary for Patent: 8,772,458

Title:	Crystalline anti-hTNFalpha antibodies
Abstract:	The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
Inventor(s):	Koenigsdorfer; Anette (Ilvesheim, DE), Gottschalk; Stefan (Grunwald, DE), Krause; Hans-Juergen (Biblis, DE), Winter; Gerhard (Penzberg, DE), Borhani; David W. (Hartsdale, NY), Fraunhofer; Wolfgang (Newton, MA)
Assignee:	AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:	13/774,706
Patent Claims:	1. A method for treating a TNFalpha-related disorder in a subject in need thereof, said method comprising the step of administering to the subject an effective amount of anti-hTNFalpha antibody crystals, wherein the antibody is an isolated human IgG antibody comprising two heavy chains each with a molecular weight of about 50 kpa, a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, and wherein the crystals have a needle-like morphology with a length 1 of about 2-500 .mu.m and an 1/d ratio of about 3 to 30. 2. A method for treating a TNFalpha-related disorder in a subject in need thereof, said method comprising the step of administering to the subject an effective amount of a pharmaceutical composition comprising: (a) crystals of an isolated human IgG anti-hTNFalpha antibody, wherein the antibody comprises two heavy chains each with a molecular weight of about 50 kpa, a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, and wherein the crystals have a needle-like morphology with a length 1 of about 2-500 .mu.m and an 1/d ratio of about 3 to 30, and (b) a pharmaceutical excipient. 3. The method according to claim 2, wherein the pharmaceutical composition is administered to the subject by parenteral route, oral route, or injection. 4. The method of claim 1 or 2, wherein said TNFalpha-related disorder is selected from the group consisting of an allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis and nephrotic syndrome; an infectious disease, transplant rejection or graft-versus-host disease, malignancy, pulmonary disorder, cardiac disorder, inflammatory bone disorders, bone resorption disease, alcoholic hepatitis, viral hepatitis, fulminant hepatitis, coagulation disturbances, burns, reperfusion injury, keloid formation, scar tissue formation, pyrexia, periodontal disease, obesity and radiation toxicity; a pulmonary disorder, a coronary disorder, a metabolic disorder, anemia, pain, a hepatic disorder, a skin disorder, a nail disorder, or vasculitis, Behcet's disease, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), restenosis, diabetes, anemia, pain, a Crohn's disease-related disorder, a hepatitis C virus infection, age-related cachexia, Alzheimer's disease, brain edema, inflammatory brain injury, chronic fatigue syndrome, dermatomyositis, drug reactions, edema in and/or around the spinal cord, familial periodic fevers, Felty's syndrome, fibrosis, glomerulonephritides (e.g. post-streptococcal glomerulonephritis or IgA nephropathy), loosening of prostheses, microscopic polyangiitis, mixed connective tissue disorder, multiple myeloma, cancer and cachexia, multiple organ disorder, myelo dysplastic syndrome, orchitism osteolysis, pancreatitis, including acute, chronic, and pancreatic abscess, periodontal disease polymyositis, progressive renal failure, pseudogout, pyoderma gangrenosum, relapsing polychondritis, rheumatic heart disease, sarcoidosis, sclerosing cholangitis, stroke, thoracoabdominal aortic aneurysm repair (TAAA), TNF receptor associated periodic syndrome (TRAPS), symptoms related to Yellow Fever vaccination, an inflammatory disease associated with the ear, chronic ear inflammation, or pediatric ear inflammation, uveitis, sciatica, prostatitis, endometriosis, choroidal neovascularization, lupus, Sjogren's syndrome, and wet macular degeneration. 5. The method of claim 2, wherein the pharmaceutical excipient embeds or encapsulates the crystals. 6. The method of claim 1 or 2, wherein the IgG antibody is selected from the group consisting of an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody. 7. The method of claim 1 or 2, wherein the antibody is an IgG1 antibody. 8. The method of claim 1 or 2, wherein the antibody is adalimumab. 9. The method of claim 2, wherein the composition has an antibody concentration greater than about 1 mg/ml. 10. The method of claim 2, wherein the composition has an antibody concentration greater than about 200 mg/ml. 11. The method of claim 1, wherein the crystal is combined with a polymeric carrier or an oil or lipid carrier. 12. The method of claim 11, wherein the polymeric carrier is a polymer selected from one or more of the group consisting of: poly(acrylic acid), poly(cyanoacrylates), poly(amino acids), poly(anhydrides), poly(depsipeptide), poly(esters), poly(lactic acid), poly(lactic-co-glycolic acid) or PLGA, poly(.beta.-hydroxybutryate), poly(caprolactone), poly(dioxanone); poly(ethylene glycol), poly(hydroxypropyl)methacrylamide, poly[(organo) phosphazene, poly(ortho esters), poly(vinyl alcohol), poly(vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycami-noglycans, sulfated polysaccharides, blends and copolymers thereof. 13. The method of claim 1 or 2, wherein said TNFalpha-related disorder is an autoimmune disease. 14. The method of claim 13, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis. 15. The method of claim 1 or 2, wherein said TNFalpha-related disorder is an intestinal disorder. 16. The method of claim 1 or 2, wherein said TNFalpha-related disorder is a spondyloarthropathy. 17. The method of claim 1 or 2, wherein said TNFalpha-related disorder is rheumatoid arthritis. 18. The method of claim 1 or 2, wherein said TNFalpha-related disorder is psoriatic arthritis. 19. The method of claim 1 or 2, wherein said TNFalpha-related disorder is psoriasis. 20. The method of claim 19, wherein the psoriasis is chronic plaque psoriasis. 21. The method of claim 1 or 2, wherein said TNFalpha-related disorder is juvenile rheumatoid arthritis (JRA).

Details for Patent 8,772,458

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2026-10-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2026-10-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2026-10-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2026-10-27